SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
74.67
-0.45 (-0.60%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close75.12
Open74.97
Bid0.00 x 0
Ask0.00 x 0
Day's Range74.24 - 75.33
52 Week Range62.88 - 86.39
Volume2,747,102
Avg. Volume2,300,835
Market Cap92.465B
Beta0.68
PE Ratio (TTM)27.02
EPS (TTM)2.76
Earnings DateOct 31, 2018
Forward Dividend & Yield3.03 (4.01%)
Ex-Dividend Date2018-05-11
1y Target Est80.32
  • A Look at Shire’s Valuation on September 19
    Market Realist11 hours ago

    A Look at Shire’s Valuation on September 19

    Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.

  • The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
    Zacks19 hours ago

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

    The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

  • Reuters3 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (£1.3 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Reuters3 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.

  • GlobeNewswire4 days ago

    Sanofi: Disclosure of trading in own shares

    Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for ...

  • Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
    Zacks4 days ago

    Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis

    Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.

  • National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis
    PR Newswire4 days ago

    National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis

    FORT MEYERS, Fla., Sept. 17, 2018 /PRNewswire/ -- The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention's (CDC's) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.

  • GlobeNewswire6 days ago

    Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)

    September 15, 2018 - Detailed results from a pivotal Phase 3 trial showed Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.

  • GlobeNewswire6 days ago

    Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)

    September 15, 2018 - Detailed results from a pivotal Phase 3 trial showed Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. There continues to be a significant unmet need for adolescents with moderate-to-severe atopic dermatitis, whose disease cannot be controlled with topical treatments. Dupixent is currently approved for use in certain adult patients with moderate-to-severe atopic dermatitis in countries including the U.S., European Union, Canada and Japan.

  • Analyzing uniQure’s Valuation Trend
    Market Realist6 days ago

    Analyzing uniQure’s Valuation Trend

    Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.

  • 5 Problematic Stocks Francis Chou Dared To Buy
    Insider Monkey7 days ago

    5 Problematic Stocks Francis Chou Dared To Buy

    Francis Chou, a well-regarded Canadian value investor,  the founder of Chou Associates Management, and Morningstar Fund Manager of the Decade in 2004, was once just an ordinary immigrant in Canada with $200 in his pocket. Even though he is Chinese, he was born and raised in India, and came to Canada looking for a job. For […]

  • Sanofi pledges to keep up its restructuring efforts
    Reuters7 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi (SASY.PA) will continue to implement cost savings after having reached a 1.5 billion euros (1.33 billion pounds) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday. The CEO did not elaborate further but referred to a reorganisation of Sanofi's global business units unveiled earlier this week.

  • Reuters7 days ago

    Sanofi pledges to keep up its restructuring efforts

    Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well. The French drugmaker, hurt by declining revenue at its diabetes business in recent years, is eyeing a return to growth from the second half of 2018 as it builds upon acquisitions made earlier this year. "It's only the beginning, and we will continue to be very efficient," Chief Executive Olivier Brandicourt told investors, regarding the cost savings, at a Bank of America Merrill Lynch conference in London on Friday.

  • Bayer's pharma unit head Weinand quits to join Sanofi
    Reuters8 days ago

    Bayer's pharma unit head Weinand quits to join Sanofi

    Bayer, which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.

  • Bayer's pharma unit head Weinand quits to join Sanofi
    Reuters8 days ago

    Bayer's pharma unit head Weinand quits to join Sanofi

    Bayer (BAYGn.DE), which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi (SASY.PA) to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs. In a statement on Thursday, Germany's Bayer said Weinand would be succeeded by Stefan Oelrich, currently a member of Sanofi's executive committee in charge of diabetes and cardiovascular businesses. For Bayer, the job swap comes in the midst of talk on job cuts and outsourcing as part of a review of its drug research and development operations, which investors say has produced few promising products.

  • The Wall Street Journal8 days ago

    [$$] Sanofi Poaches Bayer Manager to Lead Unit

    Sanofi hired the head of Bayer’s pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.

  • Sanofi and Bayer Are Swapping Executives
    Bloomberg8 days ago

    Sanofi and Bayer Are Swapping Executives

    Sanofi and Bayer AG, two European drugmakers with blockbuster medicines facing headwinds, are swapping top executives. Sanofi is bringing in Bayer’s Dieter Weinand as executive vice president in charge of a new unit that combines its diabetes and cardiovascular operations with a broader group of established products, the Paris-based company said in a statement Thursday. At the same time, Stefan Oelrich, head of diabetes at Sanofi, will replace Weinand as the head of Bayer’s pharmaceuticals division in November.

  • GlobeNewswire8 days ago

    Sanofi to refocus two global business units

    Mature Markets include the U.S., Canada, Western & Eastern Europe, Japan, South Korea, Australia, New Zealand and Puerto Rico.

  • GlobeNewswire8 days ago

    Sanofi to refocus two global business units

        Sanofi to refocus two global business units Appoints Dieter Weinand to lead new Primary Care business unit New China & Emerging Markets business to be led by Olivier Charmeil Stefan Oelrich will leave ...

  • 3 Top Value Stocks to Buy Right Now
    Motley Fool9 days ago

    3 Top Value Stocks to Buy Right Now

    This power-packed list of value stocks from diverse industries is all you need to see right now.

  • PR Newswire9 days ago

    FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

    /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE).

  • GlobeNewswire9 days ago

    FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

    September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE).

  • GlobeNewswire9 days ago

    FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

    September 12, 2018 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Praluent® (alirocumab) Injection, a PCSK9 inhibitor. The sBLA outlines a proposed update to the Prescribing Information to include the effect of Praluent in reducing the overall risk of major adverse cardiovascular events (MACE).

  • Benzinga10 days ago

    BofA Upgrades Sanofi, Names 3 Growth Drivers For Pharma Stock

    Sanofi SA (ADR) (NYSE: SNY ), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical ...

  • GlobeNewswire11 days ago

    Sanofi: Disclosure of trading in own shares

    Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for ...